Dechra Pharmaceuticals logo

DPH - Dechra Pharmaceuticals Share Price

3430p -22.0  -0.6%

Last Trade - 26/02/21

Sector
Healthcare
Size
Large Cap
Market Cap £3.71bn
Enterprise Value £3.91bn
Revenue £566.4m
Position in Universe 213th / 1807
Bullish
Bearish
Unlock DPH Revenue
Momentum
Relative Strength (%)
1m -9.62%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
203.5 247.6 359.3 407.1 481.8 515.1 582.6 631.3 +20.4%
+12.6 +4.4 +153.7 +24.2 -7.4 -2.1 +73.7 +7.46
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, DechraPharmaceuticals plc revenues increased 21% to £299.8M. Netincome increased 77% to £23.3M. Revenues reflect EuropeanPharmaceuticals segment increase of 23% to £195.6M, NAPharmaceuticals segment increase of 17% to £104.2M. Netincome benefited from European Pharmaceuticals segmentincome increase of 34% to £65M, NA Pharmaceuticals segmentincome increase of 21% to £36.3M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for DPH
Graphical History

Revenue

DPH Revenue Unlock DPH Revenue

Net Income

DPH Net Income Unlock DPH Revenue

Normalised EPS

DPH Normalised EPS Unlock DPH Revenue

PE Ratio Range

DPH PE Ratio Range Unlock DPH Revenue

Dividend Yield Range

DPH Dividend Yield Range Unlock DPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DPH EPS Forecasts Unlock DPH Revenue
Profile Summary

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated May 13, 1997
Public Since September 21, 2000
No. of Shareholders: n/a
No. of Employees: 1,808
DPH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DPH
Upcoming Events for DPH
Frequently Asked Questions for Dechra Pharmaceuticals
What is the Dechra Pharmaceuticals share price?

As of 26/02/21, shares in Dechra Pharmaceuticals are trading at 3430p, giving the company a market capitalisation of £3.71bn. This share price information is delayed by 15 minutes.

How has the Dechra Pharmaceuticals share price performed this year?

Shares in Dechra Pharmaceuticals are currently trading at 3430p and the price has moved by 28.46% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Dechra Pharmaceuticals price has moved by 24.56% over the past year.

What are the analyst and broker recommendations for Dechra Pharmaceuticals?

Of the analysts with advisory recommendations for Dechra Pharmaceuticals, there are there are currently 3 "buy" , 4 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Dechra Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Dechra Pharmaceuticals next release its financial results?

Dechra Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Dechra Pharmaceuticals dividend yield?

The Dechra Pharmaceuticals dividend yield is 1.02% based on the trailing twelve month period.

Does Dechra Pharmaceuticals pay a dividend?

Last year, Dechra Pharmaceuticals paid a total dividend of 0.35, and it currently has a trailing dividend yield of 1.02%. Looking ahead, shares in Dechra Pharmaceuticals are due to go ex-dividend on 2021-03-04 and the next dividend pay date is 2021-04-07.

When does Dechra Pharmaceuticals next pay dividends?

Dechra Pharmaceuticals are due to go ex-dividend on 2021-03-04 and the next dividend pay date is 2021-04-07. The historic dividend yield on Dechra Pharmaceuticals shares is currently 1.02%.

How do I buy Dechra Pharmaceuticals shares?

To buy shares in Dechra Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Dechra Pharmaceuticals?

Shares in Dechra Pharmaceuticals are currently trading at 3430p, giving the company a market capitalisation of £3.71bn.

Where are Dechra Pharmaceuticals shares listed? Where are Dechra Pharmaceuticals shares listed?

Here are the trading details for Dechra Pharmaceuticals:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: DPH
What kind of share is Dechra Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Dechra Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Dechra Pharmaceuticals share price forecast 2021?

Shares in Dechra Pharmaceuticals are currently priced at 3430p. At that level they are trading at 7.35% discount to the analyst consensus target price of 3,702.10.

Analysts covering Dechra Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 1.01725 for the next financial year.

How can I tell whether the Dechra Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dechra Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -5.42%. At the current price of 3430p, shares in Dechra Pharmaceuticals are trading at 5.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Dechra Pharmaceuticals PE Ratio?

The Dechra Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 53.62. The shares are currently trading at 3430p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Dechra Pharmaceuticals?

Dechra Pharmaceuticals's management team is headed by:

Ian Page - CEO
Giles Coley - OTH
Mike Eldred - CEX
Susan Longhofer - CSO
Paul Sandland - CFO
Anthony Griffin - MDR
Allen Mellor - OTH
Julian Heslop - NID
Ishbel Macpherson - NID
Katy Clough - DHR
Tony Rice - NEC
Lawson Macartney - NID
Anthony Lucas - OTH
Lisa Bright - NID
Milton McCann - OTH
Who are the major shareholders of Dechra Pharmaceuticals?

Here are the top five shareholders of Dechra Pharmaceuticals based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 8.62% (9.32m shares)
Aberdeen Standard Investments (Edinburgh) Investment Advisor
Percentage owned: 6.91% (7.47m shares)
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.17% (5.59m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.69% (3.99m shares)
Grandeur Peak Global Advisors, LLC Investment Advisor
Percentage owned: 3.01% (3.25m shares)
Similar to DPH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.